Full Press Release Details
Bacterin Receives Letter From NYSE MKT LLC Regarding Timely
Notice of Record Date
for 2012 Annual Meeting of Stockholders
BELGRADE, Mont. JULY
3, 2012 /PRNewswire/ - Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE), a leader in the development of revolutionary bone
graft material and antimicrobial coatings for medical applications, received a letter from NYSE Regulation on July 2, 2012
advising that the Company did not comply with Sections 703 and 1009 of the NYSE MKT LLC Company Guide, which required the
Company to provide the NYSE MKT LLC with ten days prior notice of the June 8, 2012 record date for its upcoming 2012 Annual
Meeting of Stockholders. The Company will file a Form 8-K with the Securities and Exchange Commission related to this matter.
The NYSE MKT LLC also notified the Company that according to Section 401(j) of the Company Guide it needed to issue a news
release. This action will NOT result in the suspension or delisting of the Company's securities.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT LLC:
BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary
methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral
repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery,
relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery
and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses
bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings
designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant
risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer
to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," "projects," "forecasts,"
"strategy," "will," "goal," "target," "prospects," "potential," "optimistic,"
"confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical
fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability
to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a
timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's
ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property;
the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness
of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes
in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills
and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including
actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under
the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except
James Carbonara, Regional Vice President, 646-755-7412
Brett Maas, 646-536-7331